[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sarcopenia-in-elderly\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sarcopenia-in-elderly":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,40,65,90,122,154,180,204,232,259,284,307,324,352,373,398,425,449,478,509,543,573,595,616,636],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100643939","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-in-207907-injection-in-elderly-patients-with-sarcopenia-100643939",false,"NCT07668180","A Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia","A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With Sarcopenia","Inclusion Criteria:\n\n* Subjects aged ≥ 65 years (for female subjects, those who are medically unable to become pregnant)\n* Subjects diagnosed with sarcopenia in accordance with the Korean Working Group on Sarcopenia (KWGS) guidelines\n* Subjects with a body weight of ≥ 35 kg and a body mass index (BMI) of ≥ 15 kg\u002Fm² and \\\u003C 30 kg\u002Fm²\n* Subjects with a nutritional status screening score of ≥ 8 as assessed by the Mini Nutritional Assessment (MNA) questionnaire\n\nExclusion Criteria:\n\n* Subjects with a history of diseases or surgical procedures that may affect physical activity or function\n* Subjects with underlying muscle disorders, including myopathy or muscular atrophy\n* Subjects with neuromuscular or neurological disorders\n* Subjects with uncontrolled diabetes mellitus, severe renal impairment, uncontrolled thyroid disorders, vitamin D deficiency, severe hepatic impairment, severe cardiac disease, uncontrolled hypertension, respiratory disorders\n* Subjects with clinically significant findings on a 12-lead electrocardiogram (ECG)\n* Subjects who are positive for active hepatitis B, active hepatitis C, syphilis, or human immunodeficiency virus\n* Subjects with a history of malignancy within 5 years\n* Subjects who have received systemic immunosuppressants or immunostimulants\n* Subjects who have undergone treatment with plasmapheresis within 8 weeks\n* Subjects who have received treatment with medications prohibited in this clinical trial within 4 weeks\n* Subjects with hemoglobin levels \\\u003C 10 g\u002FdL\n* Subjects who have undergone surgery requiring general anesthesia within 4 weeks\n* Subjects who are unable to walk or are physically inactive\n* Subjects who are participating in or planning to participate in a separate high-intensity program for increasing muscle mass or strength during the clinical trial period\n* Subjects with severe psychiatric disorders such as major depression, schizophrenia, alcoholism, or drug dependence\n* Subjects with a score of \\\u003C 24 on the Korean version of the Mini Mental State Examination (MMSE-K)\n* Subjects with known allergies or hypersensitivity to the investigational product or its excipients","ALL","65 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn if intervention can treat sarcopenia in the elderly. Researchers will compare IN-207907 120 mg, 240 mg, 360 mg and placebo to see if SPPB score improves.",[27],"Sarcopenia in Elderly","NOT_YET_RECRUITING","2026-06-19",{"date":31,"type":32},"2026-06-25","ACTUAL",{"date":34,"type":21},"2026-09",{"date":36,"type":21},"2028-02",{"name":38,"class":39},"HK inno.N Corporation","INDUSTRY",{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100615373","blood-flow-restriction-training-in-acute-geriatric-rehabilitation-100615373","NCT07291765","Blood Flow Restriction Training in Acute Geriatric Rehabilitation","Blood Flow Restriction Training in Acute Geriatric Rehabilitation: A Randomized Controlled Trial on Its Effects and Safety in Hospitalized Older Adults.","Inclusion Criteria:\n\n* Adults \\>65 years with a two week hospitalized acute rehabilitation after a fracture closed to the hip joint\n\nExclusion Criteria:\n\n* Sickle Cell Anemia\n* Iatrogenic changes of the vessels at the place of the tournqiuet application (e.g. Stents)",{"count":48,"type":21},60,[50],"NA","Background: Older adults have a reduced ability to build and maintain muscle mass due to age-related changes in the muscular system. The resulting sarcopenia can lead to a number of health problems and limitations, such as an increased risk of falling and reduced mobility, which can affect quality of life and increase the risk of disease. To increase muscle mass and strength, high-intensity resistance training with loads of 70 to 85% of the repetition maximum (1RM) is recommended. However, this type of training poses a major challenge in the rehabilitation sector, as there is also an increased risk of injury due to physical limitations in old age. According to current research, low-intensity occlusion training could therefore represent a safe and effective training alternative. The aim of this study is therefore to examine the feasibility and effects of blood flow restriction training (BFR) on general health in older adults in a rehabilitative setting.",[27],"RECRUITING","2026-05-11",{"date":56,"type":32},"2026-05-14",{"date":58,"type":32},"2026-01-01",{"date":60,"type":21},"2027-03-31",{"name":62,"class":63},"University Hospital, Bonn","OTHER",1,{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":22,"phases":75,"briefSummary":76,"conditions":77,"keywords":78,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100622971","phase-2-a-study-of-plh-2301-in-subjects-with-sarcopenia-100622971","NCT07390552","A Study of PLH-2301 in Subjects With Sarcopenia","A Prospective, Randomized, Double-blinded, Placebo-controlled, 4-Parallel Arm, Multi-center, Phase 2 Trial to Evaluate Efficacy and Safety of Orally Administered PLH-2301 in Elderly Patients With Sarcopenia","PLH-2301_P2","Inclusion Criteria:\n\n* Male or female subjects aged 65 years or older at the time of consent\n* Diagnosis of sarcopenia based on predefined diagnostic criteria\n* Short Physical Performance Battery (SPPB) total score within the protocol-defined range at screening\n* Stable body weight for at least 3 months prior to screening\n* Able to walk independently with or without assistive devices\n* Willing and able to comply with study procedures\n* Provided written informed consent prior to any study-specific procedures\n\nExclusion Criteria:\n\n* History of clinically significant neuromuscular or musculoskeletal disorders that could affect muscle function\n* Uncontrolled cardiovascular, hepatic, renal, or metabolic disease\n* Use of medications known to affect muscle mass or function within the protocol-defined washout period\n* Participation in another interventional clinical trial within 3 months prior to screening\n* Any medical or psychiatric condition that, in the investigator's opinion, would interfere with study participation",{"count":74,"type":21},168,[24],"This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia.\n\nEligible subjects aged 65 years and older will be randomized to receive placebo or one of three dose levels of PLH-2301 once daily for 12 weeks.\n\nThe primary objective is to assess the effect of PLH-2301 on physical function compared with placebo.",[27],[79],"Sarcopenia","2026-05-10",{"date":82,"type":32},"2026-05-12",{"date":84,"type":32},"2026-05-08",{"date":86,"type":21},"2027-06-30",{"name":88,"class":39},"Pluto Inc.",5,{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":102,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":121},"100639336","effects-of-aquatic-exercise-in-older-adults-with-sarcopeniaa-randomized-trial-100639336","NCT07575958","Effects of Aquatic Exercise in Older Adults With Sarcopenia:A Randomized Trial","Effects of Aquatic Exercise Program on Muscle Strength, Muscle Mass, Physical Performance and Quality of Life in Older Adults With Sarcopenia: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥65 years\n2. Diagnosis of \"definite sarcopenia\" according to the ISarcoPRM diagnostic algorithm\n3. Not receiving nutritional supplementation and not requiring nutritional support according to the Mini Nutritional Assessment (MNA)\n4. Sufficient cognitive ability to understand and follow instructions, including study-related questions and the home exercise program\n5. Voluntary participation in the study\n6. Ability to ambulate independently (assistive devices such as a cane are allowed; however, fully dependent individuals will be excluded)\n\nExclusion Criteria:\n\n1. Inability to complete assessment tests and questionnaires\n2. Presence of severe systemic disease that may contraindicate exercise\n3. Severe visual or hearing impairment\n4. Presence of a cardiac pacemaker\n5. Severe cardiopulmonary disease\n6. Uncontrolled hypertension\n7. Uncontrolled diabetes mellitus\n8. Receiving nutritional supplementation\n9. Severe anemia\n10. Conditions contraindicating hydrotherapy, including aquaphobia (fear of water), behavioral disorders, dyspnea at rest, urinary or fecal incontinence, known chlorine allergy, open wounds, acute systemic illness, epilepsy, tracheostomy, indwelling drainage devices, and immunodeficiency",{"count":98,"type":21},44,[50],"Sarcopenia is a geriatric syndrome characterized by age-related loss of skeletal muscle mass, strength, and physical performance, leading to increased risk of falls, functional decline, and reduced quality of life. Exercise interventions, particularly resistance training, are effective in managing sarcopenia; however, land-based exercises may be challenging for older adults due to balance impairments, joint problems, and fear of falling.\n\nPool-based exercise programs may offer a safe and feasible alternative, as water buoyancy reduces joint loading while providing resistance to support muscle strengthening. Despite these potential benefits, evidence regarding the effects of aquatic exercise in individuals with sarcopenia remains limited, especially in Türkiye.\n\nThis study aims to evaluate the effects of a 6-week supervised pool-based exercise program on muscle strength, muscle morphology, physical performance, mood, and quality of life in individuals aged 65 years and older with sarcopenia. Sarcopenia will be identified using the Sonographic Thigh Adjustment Ratio (STAR), based on ultrasound measurements of anterior thigh muscle thickness. In addition, appendicular skeletal muscle mass will be assessed using bioelectrical impedance analysis (ASM\u002Fheight²).\n\nOutcome measures will include ultrasound-based muscle thickness, STAR, muscle strength, functional performance tests, depressive symptoms, and health-related quality of life. Assessments will be performed at baseline, immediately after the intervention, and at 1-month follow-up.",[79,27],[103,104,105,106,107,108,109,110,111],"sarcopenia","aquatic exercise","hydrotherapy","aquatic therapy","sarcopenia ultrasound","Geriatric","Elderly","water-based exercise","Sonographic Thigh Adjustment Ratio(STAR)","2026-05-07",{"date":82,"type":32},{"date":115,"type":32},"2026-04-01",{"date":117,"type":21},"2026-07",{"name":119,"class":120},"Gaziosmanpasa Research and Education Hospital","OTHER_GOV",2,{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":12,"sex":17,"minAge":129,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":139,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":64},"100619531","the-effect-of-volunteer-engaged-lifestyle-optimisation-via-icope-on-sarcopenia-in-older-adults-velo-s-100619531","NCT07345832","The Effect of Volunteer-Engaged Lifestyle Optimisation Via ICOPE on Sarcopenia in Older Adults (VELO-S)","The Effect of Volunteer-Engaged Lifestyle Optimisation Via ICOPE on Sarcopenia in Older Adults (VELO-S): A Randomised Controlled Trial","Inclusion Criteria:\n\n1. aged 60 or above\n2. Pseudo-Sarcopenia as indicated by a score on SARC-CaIF ≥11, OR sarcopenia according relative BIA-based appendicular skeletal mass\u002F height (Men: \\\u003C7 kg\u002Fm2; women: \\\u003C5.7 kg\u002Fm2), OR handgrip strength on dominant hand (male \\\u003C28 kg, female \\\u003C18 kg) (Chen et al., 2025)\n3. the ability to use a smartphone, electronic tablet, or computer\n4. consent to participate\n\nExclusion Criteria:\n\n1. having medical conditions contradictory to physical activity including unstable cardiovascular and orthopaedic conditions\n2. engaging in other structured health promotion program involving physical activity and nutritional enhancement","60 Years",{"count":131,"type":21},200,[50],"Sarcopenia prevention and management are highly prioritised goals in the Healthy Ageing agenda. The study aims to: 1) evaluate the effects of the digital-enhanced, volunteer-engaged collaborative care pathway to improve sarcopenia, reduce fall risk, and increase health-related quality of life (HRQL) among community-dwelling older adults with risk of, or diagnosed with, sarcopenia; 2) evaluate whether the volunteers who received health coach capacity training and supported the intervention experienced health benefits across time; 3) explore the engagement experiences and perceived effects of elderly participants with sarcopenia during the program; 4) evaluate the intervention implementation process and effects from the perspectives of social care workers.",[79,27,135,136,137,138],"Fall Prevention in Healthy Aging","Frailty Syndrome","Malnutrition Elderly","Frailty",[103,140,141,142,143,144,145],"elderly","frailty","fall prevention","malnutrition","health-related quality of life","digital intervention","2026-04-30",{"date":112,"type":32},{"date":149,"type":21},"2026-06-01",{"date":151,"type":21},"2027-09-30",{"name":153,"class":63},"The University of Hong Kong",{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":17,"minAge":129,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":121},"100576428","effects-of-resistance-training-on-sarcopenia-in-older-patients-with-chronic-heart-failure-100576428","NCT06785168","Effects of Resistance Training on Sarcopenia in Older Patients With Chronic Heart Failure","Effects of Resistance Training on Sarcopenia in Older Patients With Chronic Heart Failure: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged ≥ 60 years old\n* Meet the diagnostic criteria of 2019 AWGS2 sarcopenia, can be diagnosed once meeting (1) + (2) or (1) + (3) or (1) + (2) + (3): (1) Appendicular skeletal muscle mass (ASM): dual-energy X-ray absorptiometry (DXA) (male \\\u003C7.0 kg\u002Fm², female \\\u003C5.7 kg\u002Fm²). (2) Muscle strength: handgrip strength (male \\\u003C28.0 kg, female \\\u003C18.0 kg). (3) Physical performance: 6-meter walking speed \\\u003C1.0 m\u002Fs.\n* Meet the diagnostic criteria of heart failure following ESC 2021.\n* Clearly understand the content and purpose of the study and sign the informed consent form.\n\nExclusion Criteria: There are contraindications for Exercise Testing in patients with stable heart failure according to ACSM 2022:\n\n* Early stage after acute coronary syndrome (within the first 2 days)\n* Unstable coronary artery disease\n* Decompensated heart failure\n* Acute venous thrombosis or recent arterial embolism (pulmonary or systemic)\n* Acute myocarditis, pericarditis, endocarditis\n* Aortic dissection of the valve\n* Severe symptomatic aortic stenosis\n* Acute systemic disease or fever\n* Uncontrolled or life-threatening atrial or ventricular arrhythmias (including new-onset atrial fibrillation or flutter)\n* Uncontrolled tachycardia (resting heart rate \\> 120 beats per minute)\n* Third-degree AV block\n* Uncontrolled diabetes\n* Symptomatic orthostatic hypotension (\\> 20 mmHg)\n* Gradually increasing fatigue during exercise or dyspnea at rest or with exertion within the past 3-5 days\n* Significant myocardial ischemia at low workloads \\\u003C 2 METs or 50W\n* Relative contraindications according to ACSM 2022:\n* Weight gain ≥ 1.8 kg in the past 1-3 days\n* Simultaneous use of continuous or intermittent Dobutamine\n* Decrease in blood pressure with exercise\n* NYHA IV heart failure\n* Complex ventricular arrhythmias at rest or with exertion\n* Resting heart rate ≥ 100 bpm when lying down\n* Comorbidities that limit exercise\n* Severe obstructive hypertrophic cardiomyopathy\n* Have participated in a cardiovascular rehabilitation program within the last 6 months\n* Do not agree to participate in the study",{"count":162,"type":21},146,[50],"The goal of study is to evaluate the effects of an eight-week machine-based resistance training program on managing sarcopenia in older outpatients with chronic heart failure (HF) at Military Hospital 175.",[27,166],"Chronic Heart Failure",[103,168,169,170,171],"chronic heart failure","machine-based resistance training","age over 60","outpatient","2026-04-25",{"date":146,"type":32},{"date":175,"type":32},"2024-12-24",{"date":177,"type":21},"2027-12-31",{"name":179,"class":63},"Kieu Nguyen Dang Phuong",{"id":181,"slug":182,"hasResults":12,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":12,"sex":17,"minAge":129,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":189,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":64},"100634360","phase-2-peiyuan-guben-tongluo-ointment-for-elderly-sarcopenia-100634360","NCT07538674","Peiyuan Guben Tongluo Ointment for Elderly Sarcopenia","A Randomized, Double-Blind Clinical Study of Peiyuan Guben Tongluo Ointment in the Treatment of Elderly Sarcopenia (Spleen-Kidney Deficiency Syndrome) With Two Internal and External Controls","Inclusion Criteria:\n\n* Patients aged ≥ 60 years and ≤ 80 years, regardless of gender; ② Patients meeting the diagnostic criteria for sarcopenia in the elderly according to both traditional Chinese medicine (TCM) and Western medicine;\n\n  * Patients meeting the TCM diagnostic criteria for Spleen-Kidney Deficiency Syndrome;\n\n    * Able to take oral medications, willing to comply with the study intervention protocol, able to attend follow-up visits on time, and have signed the informed consent form.\n\nExclusion Criteria:\n\n* Patients with quadriplegia, long-term bedridden status, zero muscle strength due to severe cerebrovascular accident, muscle atrophy caused by various factors, or inability to perform activities of daily living;\n\n  * Patients with unclear consciousness, aphasia, delirium, inability to respond, or impaired time, location and orientation due to senile or vascular dementia;\n\n    * Patients with severe mental illness, depressive state, or receiving relevant psychotropic medication; ④ Patients complicated with tumors, severe infections, gastrointestinal bleeding, hepatic and renal insufficiency, cardiac insufficiency, or other diseases affecting nutritional status; ⑤ Patients with hypersensitivity to the study drugs; patients who have received or are receiving traditional Chinese medicine treatment within the past 1 month; patients who have received medications affecting muscle contraction\u002Frelaxation within the past 1 month.","80 Years",{"count":48,"type":21},[24],"With the agarose concentrating group of Peiyuan Guben Tongluo Ointment set as the parallel control and an external control established simultaneously, this study aimed to evaluate the increases from baseline in DXA-measured limb muscle mass after 12 weeks of medication in elderly sarcopenia patients treated with the Ejiao concentrating group of Peiyuan Guben Tongluo Ointment.",[27],[27,193,194],"Deficiency of Spleen and Kidney Yin","Peiyuan Guben Tongluo Ointment","2026-04-15",{"date":197,"type":32},"2026-04-20",{"date":199,"type":21},"2026-04",{"date":201,"type":21},"2028-12-31",{"name":203,"class":63},"Shanghai Yueyang Integrated Medicine Hospital",{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":12,"sex":17,"minAge":211,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":221,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":228,"leadSponsor":230,"locationsCount":64},"100578440","phase-2-effects-of-tirzepatide-on-muscle-and-vascular-health-in-obese-older-adults-100578440","NCT06811324","Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults","The Effects of Tirzepatide Use on Muscle and Vascular Function Among Obese Older Adults","Inclusion Criteria\n\n* Men and postmenopausal women aged 50 years or older.\n* Body Mass Index (BMI) ≥30 kg\u002Fm².\n* Untreated HbA1c \\\u003C6.5% at baseline.\n* Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.\n* Able to provide informed consent and participate in all study assessments.\n\nExclusion Criteria\n\n* Active diagnosis of type 2 diabetes mellitus (T2DM), defined by active use of glucose-lowering medications or hemoglobin A1c ≥ 6.5%.\n* Body Mass Index (BMI) ≥ 40 kg\u002Fm².\n* Moderate to severe gastroesophageal reflux disease based on patient history.\n* Inability to comply with the treatment protocol or to understand the consent form.\n* Chronic Kidney Disease (CKD) Stage 4.\n* Aspartate aminotransferase (AST) \\> 33 U\u002FL or alanine aminotransferase (ALT) \\> 36 U\u002FL.\n* Active pregnancy.\n* Personal or family history of medullary thyroid carcinoma.\n* Personal or family history of multiple endocrine neoplasia type 2 syndrome.\n* Personal history of gastroparesis.\n* Personal history of diabetic retinopathy.\n* Known serious hypersensitivity, including anaphylaxis and angioedema, to Tirzepatide or any of its excipients.\n* Known serious hypersensitivity, including anaphylaxis and angioedema, to any GLP-1 receptor agonist class of therapies.\n* Concomitant treatment with GLP-1 receptor agonist therapy","50 Years",{"count":213,"type":21},20,[24],"Obesity and type 2 diabetes mellitus (T2DM) represent major public health concerns in the aging community. Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist recently approved for the treatment of T2DM and obesity has been shown to be effective at reducing weight, improving markers of T2DM control, and improving cardiovascular health. Utilization of tirzepatide among older adults has been on the rise since FDA approval was issued, however the effects of tirzepatide use on functional outcomes in older adults with obesity are not well established. Recent studies show that weight loss caused by tirzepatide may be driven by substantial loss of lean muscle mass, which may contribute to weakness and frailty, particularly among older adults. The proposed pilot study aims to evaluate how treatment with tirzepatide for 6 months affects muscle mass and function among older adults, and if changes in muscle mass are linked to changes in functional status over the same time period.",[217,27,218,219,220],"Obesity Prevention","Cardiovascular Function","GLP - 1","Weight Loss",[222,223,224,79,218],"Tirzepatide","GLP-1","Obesity","2026-04-10",{"date":195,"type":32},{"date":115,"type":32},{"date":229,"type":21},"2027-06-01",{"name":231,"class":63},"The University of Texas Health Science Center at San Antonio",{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":64},"100587245","effect-of-micronized-creatine-monohydrate-on-muscle-mass-strength-and-performance-in-older-adults-submitted-to-total-knee-arthroplasty-100587245","NCT06925880","Effect of Micronized Creatine Monohydrate on Muscle Mass, Strength and Performance in Older Adults Submitted to Total Knee Arthroplasty","Efficacy of Supplementation With Micronized Creatine Monohydrate in the Recovery of Muscle Mass, Muscle Strength and Functional Capacity in Older Adults Operated on for Total Knee Arthroplasty: Randomized Clinical Trial","CREAR","Inclusion Criteria:\n\n* Persons 65 years of age or older who have been operated on for the first time for total knee arthroplasty,\n* who are undergoing an outpatient rehabilitation program according to standard clinical practice,\n* who sign the informed consent form.\n\nExclusion Criteria:\n\n* Chronic renal disease at stage G3b or higher or glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73m2.\n* Hepatic insufficiency, cirrhosis.\n* Neuromuscular and neurodegenerative diseases (amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, myasthenia gravis, Parkinson's disease, etc.).\n* Severe or very severe chronic obstructive pulmonary disease (COPD) (GOLD III-IV).\n* Moderate or severe chronic heart failure (NYHA 3-4).\n* Central sensitivity syndrome (fibromyalgia and chronic fatigue syndrome).\n* Moderate or severe cognitive impairment (GDS≥4).\n* Moderate-severe dependence for basic activities of daily living (preintervention Barthel index \\\u003C60 points).\n* Hemiparesis, amputation or malformation of any limb.\n* Consumption of creatine monohydrate supplements in the last 6 months.",{"count":241,"type":21},262,[50],"Double-blind randomized placebo-controlled clinical trial with two parallel arms. The main objective is to evaluate the efficacy and safety of creatine supplementation in older adults who have been operated on for total knee arthroplasty and undergoing a usual rehabilitation program. The intervention will consist of daily creatine monohydrate supplementation for 12 weeks. The intervention will start after surgery with a loading dose of 20g\u002Fday for 1 week and then continue with a maintenance dose of 5g\u002Fday for 11 weeks.\n\nMain outcome mesures included muscle mass, muscle strenght, sarcopenia, frailty, functional capacity and physical performance and will be assessed at baseline, 3 and 6 months follow-up.",[27,245,246,247,248,249],"Frailty at Older Adults","Functional Capacity","Creatine Supplementation","Arthroplasties, Knee Replacement","Physical Performance","2026-03-25",{"date":252,"type":32},"2026-03-30",{"date":254,"type":32},"2025-06-10",{"date":256,"type":21},"2027-10-31",{"name":258,"class":63},"Consorci Sanitari del Maresme",{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":17,"minAge":129,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":267,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":276,"lastUpdatePostDateStruct":277,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":282,"locationsCount":64},"100581666","the-influence-of-movement-velocity-biofeedback-on-muscle-activation-and-self-perception-in-older-adults-with-sarcopenia-100581666","NCT06853275","The Influence of Movement Velocity Biofeedback on Muscle Activation and Self Perception in Older Adults With Sarcopenia","Inclusion Criteria:\n\n* Community-dwelling older adults 60-95 years of age\n* Physically independent\n* Free of severe mental impairment\n* Score 4 or greater on the SARC-F sarcopenia questionnaire\n\nExclusion Criteria:\n\n* Participated in a structured resistance training program in the last 12 months\n* Had a lower extremity injury or surgical intervention within the past 6 months\n* Have neuromuscular (i.e., Parkinson's Disease, Multiple Sclerosis), circulatory, or edema pathology","95 Years",{"count":48,"type":21},[50],"The overall objective for this clinical trial is to provide evidence for internal and external cueing for physical therapists and other rehabilitation clinicians to optimize resistance training within rehabilitation for older adults. The main questions it aims to answer are:\n\n* What is the impact of external focus (providing velocity of movement for each repetition) compared to internal focus (i.e., no cues, control group) on physical percent velocity loss and neuromuscular activation in older adults with sarcopenia?\n* Does internal and external focus influence motivation and perceptual workload following resistance training in older adults with sarcopenia?\n\nResearchers will compare external focus to internal focus to see if external focus impacts percent velocity loss, motivation, and perceived workload.\n\nParticipants will:\n\n* Visit the lab once per week for 3 weeks\n* Perform exercise testing using a leg press\n* Answer questionnaires regarding perceived workload and motivation before and after exercise",[79,27,270],"Age-associated Muscle Loss",[272,273,274,79,275],"Geriatrics","Neuromuscular","Rehabilitation","Velocity-based training","2026-03-16",{"date":278,"type":32},"2026-03-18",{"date":280,"type":32},"2025-08-01",{"date":177,"type":21},{"name":283,"class":63},"Creighton University",{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":294,"phases":4,"briefSummary":295,"conditions":296,"keywords":297,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":303,"leadSponsor":305,"locationsCount":4},"100627909","acute-sarcopenia-in-hospitalized-older-adults-100627909","NCT07454759","Acute Sarcopenia in Hospitalized Older Adults","Towards Better Detection of Acute Sarcopenia in Hospitalized Older Adults: Integrating Clinical and Ultrasound Approaches","BASIS","Inclusion Criteria:\n\n* Patients aged 65 years or older.\n* Hospital admission for an acute medical condition\n\nExclusion Criteria:\n\n* Presence of pre-existing neuromuscular disorders.\n* Diagnosis of terminal illness with life expectancy less than 30 days\n* Refuse to sign written informed consent",{"count":293,"type":21},280,"OBSERVATIONAL","Acute sarcopenia is a rapid decline in muscle mass and function occurring within 28 days of a major stressor, such as hospitalization, infection, or surgery. It is frequent but often underdiagnosed in older adult. Current standard of care lacks systematic strategies for its early detection and risk stratification. This study therefore proposes to combine established clinical and instrumental assessments (handgrip dynamometry, bioelectrical impedance analysis, ultrasound of the anterior thigh) to better characterize the risk factors, and outcomes of acute sarcopenia in hospitalized patients aged 65 years or older.\n\nThe study hypothesis is that the use of a systematic objective clinical assessments will improve early detection and risk stratification of this condition and the detection of acute sarcopenia related outcomes.\n\nThis is a prospective observational cohort study that will be conducted in the Emergency Department and Medical Wards of the San Raffaele Hospital.\n\nStudies objectives will include:\n\n* Determination of the incidence of acute sarcopenia\n* Identification of clinical and demographic risk factors for acute sarcopenia and relevant clinical outcomes associated with this condition",[79,27],[103,298],"acute sarcopenia","2026-03-04",{"date":301,"type":32},"2026-03-06",{"date":149,"type":21},{"date":304,"type":21},"2027-05-01",{"name":306,"class":63},"IRCCS San Raffaele",{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":294,"phases":4,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":322,"locationsCount":64},"100608208","relationship-between-swallowing-dynamics-and-suprahyoid-muscle-activity-in-sarcopenic-dysphagia-100608208","NCT07198568","Relationship Between Swallowing Dynamics and Suprahyoid Muscle Activity in Sarcopenic Dysphagia","Inclusion Criteria:\n\n* 65 years of age or older who underwent VFSS to evaluate the presence of dysphagia\n* Patient who diagnosed with sarcopenia based on the cutoff values of the Asian Working Group for Sarcopenia (AWGS) 2019\n* Cognitive ability to follow instructions for Videofluoroscopic swallowing study, surface electromyography.\n\nExclusion Criteria:\n\n* History of cerebral hemorrhage or cerebral infarction\n* History of neuromuscular diseases that could lead to dysphagia such as Parkinson's disease, amyotrophic lateral sclerosis, Guillain-Barre disease\n* History of Tracheostomy\n* History of oropharyngeal cancer\n* History of esophageal structural disease that could lead to dysphagia\n* History of connective tissue disease\n* History of cervical surgical procedure\n* Cognitive impairment who cannot follow instructions for Videofluoroscopic swallowing study, surface electromyography",{"count":314,"type":21},50,"Sarcopenic dysphagia is defined as swallowing difficulty among the elderly due to the loss of whole body skeletal and swallowing muscle mass and function. However, the pathophysiology and dynamics of swallowing in sarcopenic dysphagia have been poorly investigated. Therefore, the present study aims to investigate the characteristics of sarcopenic dysphagia using the Videofluoroscopic study (VFSS) focusing on each phase of dysphagia, and surface Electromyography (surface EMG) to assess suprahyoid muscle activity.\n\nIn sarcopenic dysphagia, impairments will occur in both the oral and pharyngeal phases, particularly affecting bolus formation, premature bolus spillage and laryngeal elevation during swallowing due to the loss of swallowing muscle mass and function. These changes will be considered to have led to an change of duration and amplitude of suprahyoid muscle activity measured via surface EMG.",[27,317],"Dysphagia",{"date":301,"type":32},{"date":320,"type":32},"2024-06-03",{"date":199,"type":21},{"name":323,"class":63},"Inha University Hospital",{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":331,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":294,"phases":4,"briefSummary":334,"conditions":335,"keywords":336,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":64},"100624842","muscle-strength-asymmetry-in-sarkopenic-and-non-sarcopenic-older-adults-100624842","NCT07414888","Muscle Strength Asymmetry In Sarkopenic And Non-sarcopenic Older Adults","Comparison of Dominant and Non-Dominant Side Muscle Strength Asymmetry in Sarcopenic and Non-Sarcopenic Older Adults","Inclusion Criteria:\n\n* Age 65 years or older\n* Ability to walk independently or with minimal assistance\n* Ability to understand and follow simple instructions\n* Willingness and ability to provide written informed consent\n* Availability of muscle strength measurements (handgrip, biceps, and quadriceps)\n\nExclusion Criteria:\n\n* Lack of cooperation, moderate to severe dementia (e.g., MMSE \\\u003C24) or conditions impeding cooperation.\n* Those with severe cardiovascular disease\n* Those with pacemakers\n* Surgical\u002Ffracture\u002Facute pain in the measured extremities within the last 6 months.\n* Neurological and muscular disease affecting the upper or lower extremity (acute stroke, severe peripheral neuropathy, etc.)\n* Active systemic disease attack significantly affecting the measurement.",true,{"count":333,"type":21},140,"The purpose of this observational study is to examine whether differences in muscle strength between the dominant and non-dominant sides of the body are associated with sarcopenia in older adults. The study will include adults aged 65 years and older with and without sarcopenia. Muscle strength will be measured on both sides of the body using handgrip strength as well as strength measurements of the biceps (upper arm muscle) and quadriceps (thigh muscle). The difference in strength between the dominant and non-dominant sides will be calculated and compared between participants with sarcopenia and those without sarcopenia.\n\nThe main question it aims to answers are:\n\n* Do older adults with sarcopenia have larger differences in muscle strength between the two sides of the body compared with those without sarcopenia?\n* Can differences in arm and leg muscle strength help identify older adults who may be at higher risk of sarcopenia?",[27],[103,337,338,339,340,341,342],"Muscle Strength Asymmetry","Handgrip","Quadriceps","Biceps","Dominant","Non dominant","2026-03-03",{"date":345,"type":32},"2026-03-05",{"date":347,"type":21},"2026-02-12",{"date":349,"type":21},"2026-03-12",{"name":351,"class":120},"Istanbul Physical Medicine Rehabilitation Training and Research Hospital",{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":22,"phases":359,"briefSummary":360,"conditions":361,"keywords":362,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":64},"100589108","evaluation-of-the-juice-ha-as-an-anti-sarcopenia-100589108","NCT06950125","Evaluation of the JUICE HA® as an Anti-sarcopenia","Inclusion Criteria:\n\n* Participants that have been diagnosed with sarcopenia by a physician and meet the AWGS 2019 criteria for sarcopenia.\n\nExclusion Criteria:\n\n* Participants with a history of severe lower extremity musculoskeletal injuries within the past six months or those who have a fear of blood sampling will be excluded.",{"count":48,"type":21},[50],"This study plans to recruit 60 participants aged 65 years and older who have been diagnosed with sarcopenia by a physician. Participants will be randomly assigned into JUICE HA® supplement and placebo group. All of the participants will be asked to take 15 mL\u002Fday of JUICE HA® supplement or placebo group for 12 weeks. The aim of this trial is to evaluate the potential of JUICE HA® to enhance physiological status (muscle mass and functional fitness) and to improve the quality of life in patients with sarcopenia.",[27],[103,363],"quality of life","2026-02-26",{"date":366,"type":32},"2026-02-27",{"date":368,"type":32},"2025-06-23",{"date":370,"type":21},"2026-03-13",{"name":372,"class":63},"China Medical University Hospital",{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":17,"minAge":380,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":382,"briefSummary":383,"conditions":384,"keywords":387,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":64},"100626001","impact-of-pre-operative-sarcopenia-on-functional-recovery-after-hip-arthroplasty-in-older-adults-100626001","NCT07429955","Impact of Pre-operative Sarcopenia on Functional Recovery After Hip Arthroplasty in Older Adults","HIP-REGEN","Inclusion Criteria:\n\n\\- Elderly subjects undergoing surgical hip replacement for fracture of the upper end of the femur or severe hip osteoarthritis.\n\nExclusion Criteria for both groups :\n\n* Contraindications to MRI : pacemaker, metallic implants.\n* Presence of a lower-limb prosthesis on the contralateral side to the surgery that may interfere with quadriceps mass measurements.\n* Progressive high-grade neoplasia.\n* Documented major cognitive disorders\n* Under legal protection measures (guardianship, conservatorship, or curatorship).\n* Subjects not affiliated with or not covered by a social security system.\n* Participation in another ongoing study with an active exclusion period.\n\nExclusion criteria - Fracture group :\n\n* Fracture with a suspicion of underlying neoplasia.\n* Placement of a lower-limb prosthesis on the surgical side within the last 12 months.\n* Inability to walk with or without human\u002Ftechnical assistance prior to fracture.\n\nExclusion criteria - Hip osteoarthritis group :\n\n\\- Active inflammatory joint disease (rheumatoid arthritis, spondyloarthritis).","75 Years",{"count":213,"type":21},[50],"This single-centre, exploratory study at Montpellier University Hospital will investigate whether having low muscle mass and strength before hip-replacement surgery, a condition called sarcopenia, impact the return to everyday independence in people aged 75 years or older. About 20 volunteers, scheduled for surgery because of a recent femoral-neck fracture or severe arthritis that no longer responds to usual care, will give consent, answer brief health questionnaires, attempt simple walking and chair-rise tests if possible, and provide a small blood sample. While they are already under anaesthesia for their planned operation, the surgical team will take a tiny muscle sample through the same incision, so no extra cuts are needed. During the hospital stay or shortly after discharge, each participant will have a painless MRI scan of the thigh muscles and a very-low-dose bone scan (DXA) to measure muscle and bone health. The research team will then telephone participants at 3 and 6 months to ask about daily activities, walking ability, and any complications. The study lasts about six months for each person and does not alter their usual medical or rehabilitation care. Potential benefits include close follow-up, personalised feedback on muscle and bone results, and helping doctors learn whether pre-surgery muscle weakness predicts slower recovery-information that could guide future, more personalised exercise and nutrition programs. Extra study procedures carry only minimal risks: a routine blood draw, scans with none (MRI) or very little (DXA) radiation, and a muscle biopsy taken during surgery. Taking part is entirely voluntary, and participants may withdraw at any time without affecting their current or future care. The whole project will run for 18 months.",[27,385,386],"Osteoarthritis (OA)","Hip Fracture Surgeries",[27,385,386,388,274],"Functional Recovery","2026-02-17",{"date":391,"type":32},"2026-02-24",{"date":393,"type":21},"2026-02",{"date":395,"type":21},"2027-08",{"name":397,"class":63},"University Hospital, Montpellier",{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":331,"sex":17,"minAge":404,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":22,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":64},"100569082","effects-of-whole-body-electrical-muscle-stimulation-exercise-on-spinal-motoneuronal-activation-in-older-adults-100569082","NCT06689618","Effects of Whole-body Electrical Muscle Stimulation Exercise on Spinal Motoneuronal Activation in Older Adults","Inclusion Criteria:\n\n* Age (65 years or older) for healthy older adults and between 18-39 for healthy younger adults\n* Ambulatory without an assistive device\n* More than anti-gravity strength in major muscle groups as assessed by manual muscle testing\n* Medical clearance to participate in an exercise program\n* Ability to conform to the requirements of the study (i.e. attendance at assessment and intervention visits, maintain current level of non-study physical activity for the duration of the study, no intention to relocate mid-study)\n\nExclusion Criteria:\n\n* Regular use of an assistive device for mobility (i.e. cane, walker, wheelchair)\n* Presence of a pacemaker, metal implants, or other implanted medical devices that could impact participant safety during WB-EMS intervention\n* Known pregnancy at the time of screening\n* Presence of unstable acute or chronic disease (i.e. renal failure, rheumatologic disease cardia arrhythmia, neoplasm, uncontrolled hypertension)\n* Presence of terminal disease (i.e. receiving hospice services)\n* Current of previous use of any drugs known to influence muscle mass or performance within 6 months; these may include but are not limited to anabolic steroids, IGF01, growth hormone, replacement and androgen therapy, anti-androgen therapy.\n* Known neuromuscular or neurologic condition affecting somatosensory or motor function\u002Fcontrol (i.e. motor neuron disease, muscle disease, severe peripheral neuropathy, NMJ disease, Parkinson's disease, Multiple Sclerosis, h\u002Fo stroke, TBI, SCI, ataxia, apraxia, hemiplegia, etc.)\n* Musculoskeletal condition or surgery in the past year that would confound results of exercise interventions (i.e. TKA, THA, RTC repair, spinal fusion)\n* Other medical conditions, signs, or symptoms that would interfere with study conduct or interpretation of results as determined by a PI","18 Years",{"count":406,"type":21},12,[50],"During this pilot study, the investigators will examine the effects of whole-body electrical muscle stimulation exercise (WB-EMS Exercise) on motoneuronal activation in healthy adults, which typically decreases with age. The investigators will also test whether WB-EMS Exercise will improve measures of physical function. Participants will undergo clinical and electrophysiologic testing before and after the WB-EMS Exercise intervention. The WB-EMS Exercise intervention will be delivered two times per week for four weeks. The hypothesis is that whole-body electrical muscle stimulation combined with physical exercise (WB-EMS Exercise) could bypass the problem of insufficient motoneuronal activation to improve exercise effect in older adults.",[410,79,27],"Aging",[410,412,413,414,79,415,416],"Motoneuronal Activation","Electrical Stimulation","Whole-Body Stimulation","Exercise Intervention","Exercise","2026-02-11",{"date":389,"type":32},{"date":420,"type":32},"2025-08-18",{"date":422,"type":21},"2026-06",{"name":424,"class":63},"University of Missouri-Columbia",{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":432,"targetDuration":434,"studyType":294,"phases":4,"briefSummary":435,"conditions":436,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":64},"100624649","predictive-factors-for-functional-and-quality-of-life-decline-in-patients-65-years-with-a-gastrointestinal-tract-cancer-diagnosis-taken-to-curative-resectable-surgery-100624649","NCT07412379","Predictive Factors for Functional and Quality of Life Decline in Patients >65 Years With a Gastrointestinal Tract Cancer Diagnosis Taken to Curative Resectable Surgery","Predictive Factors Associated With Functional Decline and Quality of Life Decline at 12 Months Follow-up and 5 Year Oncological Follow-up in Patients >65 Yares With a Gastrointestinal Tract Cancer Diagnosis Taken to Resectable Surgery With a Curative Intent in Hospital Universitario Mayor-Méderi, Bogotá, Colombia","Inclusion Criteria:\n\n* Gastrointestinal cancer tract diagnosis (oesophagus, stomach, duodenum, pancreas, liver, biliary tract, small bowel, appendix, colon and rectum)\n* Have resectable disease by surgery\n* Taken to surgery by curative intent\n* Willingness to participate and enrollment by informed consent\n* Attended in the Mederi Hospital Networn\n\nExclusion Criteria:\n\n* Mortality\n* Loss to follow-up\n* Not taken to surgery\n* Emergency surgery\n* Taken to surgery as an oncological relapse or due to complications previous to an index procedure\n* Endoscopical treatment\n* Second primary tumor without a minimum 5 year disease free period from the primary one\n* Basal functionality 0\u002F6 by Katz score.",{"count":433,"type":21},327,"5 Years","Introduction: Human life expectancy has increased significantly, leading to a transformation in the global demographic structure. Cancer is considerably more common among older adults compared to younger populations, as age is one of the main risk factors for its development. In fact, most solid tumors are considered age-related diseases. For this reason, the incidence of cancer among older individuals is expected to continue rising. Oncological care for this population group is particularly complex and represents a significant challenge, as comorbidities and the social aspects of aging create clinical scenarios that differ greatly from those seen in younger patients.\n\nObjective: To identify the predictive factors of functional decline and quality of life at 12 months of follow-up, as well as oncological outcomes at 5 years of follow-up, in patients aged 65 years and older with gastrointestinal cancer who undergo curative-intent resective surgery at Hospital Universitario Mayor - Méderi, Bogotá, Colombia.\n\nMethodology: Longitudinal and analytical observational study of prospective prognostic cohort type.\n\nExpected Results: Predictive model of functional decline and quality of life, as well as oncological outcomes, in patients with gastrointestinal cancer undergoing curative-intent surgical procedures.",[437,438,439,27,440],"Cancer Abdomen","Elderly (People Aged 65 or More)","Quality of Life","Functional Autonomy Level","2026-02-09",{"date":389,"type":32},{"date":444,"type":32},"2026-01-13",{"date":446,"type":21},"2029-12-15",{"name":448,"class":63},"Hospital Universitario Mayor Méderi",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":457,"targetDuration":4,"studyType":22,"phases":459,"briefSummary":460,"conditions":461,"keywords":464,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":64},"100621666","preventing-hospital-associated-disability-in-older-patients-individualized-nutrition-and-exercise-strategy-100621666","NCT07373587","Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy","Preventing Hospital Associated Disability in Older Patients: Individualized Nutrition and Exercise Strategy, a Randomized Controlled Trial","PrevHAD RCT","Inclusion Criteria:\n\n* Hospitalized at the geriatric ward\n* Speak Danish or English\n* Ability to give informed consent\n\nExclusion Criteria:\n\n* Moderate to severe Dementia\n* Manifest delirium",{"count":458,"type":21},360,[50],"Aproximately a third of persons older than 70 years lose physical function and ability to take care of themselves during a stay at a hospital. This is associated to an increased risk of readmission and mortality. Earlier research has shown that insufficient nutrition and physical activity during hospital stay, leading to a loss in muscle mass and strength, plays an important role in this fall in functionality. This study aims to examine if a structured and supervised resistance and mobility exercise intervention, can prevent this fall in functional ability during hospital stay among older patients. The Impact of nutritional status will be investigated by registrering caloric, protein and hydtrational intake during the study period.",[27,462,137,463],"Hospital Associated Disability","Physical Function",[465,466,79,467,468],"Older","Hospitalized","Malnutrition","Exercise intervention","2026-01-28",{"date":471,"type":32},"2026-01-30",{"date":473,"type":21},"2026-02-03",{"date":475,"type":21},"2028-02-29",{"name":477,"class":63},"Bispebjerg Hospital",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":294,"phases":4,"briefSummary":486,"conditions":487,"keywords":493,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":64},"100592034","frailty-and-muscle-strength-tests-in-older-adults-undergoing-major-surgery-100592034","NCT06988176","Frailty and Muscle Strength Tests in Older Adults Undergoing Major Surgery","Feasibility and Correlation of Functional Muscle Strength Tests and Objective Frailty Measures With Clinical Frailty Scale in Patients Undergoing Major Surgery","Inclusion Criteria:\n\nParticipants may be eligible for this study if they meet the following conditions:\n\n* Age 65 years or older.\n* Scheduled for elective (planned, non-emergency) major abdominal surgery, including colorectal, hepatobiliary, gynecologic, or urologic procedures.\n* Able to attend a routine preoperative evaluation visit.\n* Able and willing to complete brief assessments for muscle strength, walking, breathing strength, memory, and nutrition.\n\nExclusion Criteria:\n\nParticipants will not be eligible for the study if they have any of the following conditions:\n\n* Surgery is an emergency procedure.\n* Unable to walk independently (for example, dependent on a wheelchair or bed-bound).\n* Significant cognitive impairment that prevents understanding or completing study tests.",{"count":20,"type":21},"The goal of this observational study is to learn if simple tests for frailty and muscle strength can help predict which older adults (age 65 and older) are at higher risk for problems after major abdominal surgery.\n\nThe main questions it aims to answer are:\n\n* Do measures of frailty and muscle strength, taken before surgery, predict complications after surgery?\n* Can these tests be easily done during a routine pre-surgical visit?\n\nParticipants will:\n\n* Complete brief tests measuring muscle strength, breathing strength, physical function, nutrition status, body composition, and memory during a regular pre-surgical clinic appointment.\n* Allow researchers to review their medical records 30 and 90 days after surgery to identify any complications or health problems.",[138,79,27,488,489,490,491,438,492],"Muscle Strength","Post Operative Complications","Nutrition Assessment","Risk Assessment","Hand Strength",[138,103,494,495,492,496,497,491,490,498,499,500],"elective abdominal surgery","Muscle strength","Inspiratory muscle strength","Post operative complications","Elderly patients","Cognitive Function","Physical functional performance","2026-01-27",{"date":469,"type":32},{"date":504,"type":32},"2025-06-19",{"date":506,"type":21},"2026-08",{"name":508,"class":63},"University of North Carolina, Chapel Hill",{"id":510,"slug":511,"hasResults":12,"nctId":512,"briefTitle":513,"officialTitle":514,"acronym":4,"eligibilityCriteria":515,"healthyVolunteers":12,"sex":17,"minAge":129,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":518,"briefSummary":519,"conditions":520,"keywords":525,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":121},"100617748","the-effects-of-medidrink-platinum-and-fava-bean-protein-hydrolysate-on-fitness-in-an-aged-population-100617748","NCT07322653","The Effects of MediDrink Platinum+ and Fava Bean Protein Hydrolysate on Fitness in an Aged Population","Prospective, Open-Label, Multicenter Study to Characterise the Effects of Co-administration of MediDrink Platinum+ Formula Containing Novel Protein Blend SPR-01 and Fava Bean Protein Hydrolysate on Fitness in an Aged Population","Inclusion Criteria:\n\n* 60 years or older\n* BMI ≤ 25 kg\u002Fm²\n* Malnourished (mini nutritional assessment MNA \\\u003C11\n* Sarcopenic: SARC-F score ≥ 4\n* Capable or oral feeding either alone or assisted\n* Ambulatory (WHO PS\u002FECOG 0-3)\n* Ability to complete questionnaires and self assess health status\n* Ability to provide consent\n\nExclusion Criteria:\n\n* Patient cannot eat orally\n* Acute Infection\n* Proven Intestinal obstruction\n* Co-morbidities requiring a special diet (diabetes, kidney disease etc.)\n* Liver dysfunction\n* Acute or chronic renal failure\n* Uncontrollable nausea or vomiting\n* Use of megestrol acetate or metabolic steroids\n* Dietary supplement use in the last 3 months\n* Known intolerance or allergy to the investigational products\n* Participation in any clinical trial within the last 3 months",{"count":517,"type":21},75,[50],"Examining the effects of MediDrink Platinum+ containing novel protein blend SRP-01 alone or when combined with PeptiStrong on clinical responses in elderly adults with sarcopenia",[27,521,522,523,463,524],"Malnourished","Protein Supplementation","Muscle Mass","Strength",[79,526,527,528,529,530,531,532,533],"Peptide Therapeutics","PeptiStrong","MediDrink Platinum","Malnourished Elderly","Physical functioning","MediDrink Platinum+","Clinical Nurtition","Nutritional status","2025-12-22",{"date":536,"type":32},"2026-01-07",{"date":538,"type":32},"2025-09-10",{"date":540,"type":21},"2027-01-02",{"name":542,"class":39},"Nuritas Ltd",{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":22,"phases":551,"briefSummary":552,"conditions":553,"keywords":557,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":567,"completionDateStruct":569,"leadSponsor":571,"locationsCount":4},"100600659","comparing-sarcopenia--physical-psychological-and-social-frailty-in-hospitalized-older-women-congestive-heart-failure-in-metropolitan-and-rural-settings-100600659","NCT07100366","Comparing Sarcopenia , Physical, Psychological and Social Frailty in Hospitalized Older Women Congestive Heart Failure in Metropolitan and Rural Settings","Comparing Sarcopenia, Physical, Psychological and Social Frailty in Hospitalized Older Women Congestive Heart Failure (CHF) in Metropolitan and Rural Settings: a 3-Year Longitudinal Study Incorporating Information and Communication Technology (ICT) Interventions.","Inclusion Criteria:\n\n* Participants must be 65 years or older.\n* Diagnosis of CHF with a left ventricular ejection fraction (EF) of less than 40%\n* Ability to communicate effectively in Mandarin or Taiwanese.\n\nExclusion Criteria:\n\n* Patients diagnosed with unstable heart failure\n* Severe Comorbidities, conditions such as end-stage renal disease, advanced hepatic dysfunction, or terminal malignancies.\n* Severe cognitive deficits that impede the ability to provide informed consent or participate in study interventions.\n* Uncorrected visual or hearing impairments that would hinder effective communication or interaction with the ChatGPT application.\n* Active psychiatric conditions, including major depression or psychosis, that could interfere with study participation or adherence.",{"count":131,"type":21},[50],"Frailty-encompassing sarcopenia, physical, psychological, and social frailty-is common among older adults with congestive heart failure (CHF) and contributes to adverse outcomes such as rehospitalization, mortality, and poor quality of life. However, few studies have compared these conditions in congestive heart failure (CHF) patients, particularly in elderly women in Taiwan, and effective, tailored Information and Communication Technology (ICT) interventions are scarce.\n\nThis three-year study aims to (1) compare baseline characteristics and incidence rates of sarcopenia, physical, psychological, and social frailty among hospitalized older women with congestive heart failure (CHF) in metropolitan versus rural hospitals; (2) evaluate risk factors associated with physical, psychological, and social frailty; (3) monitor health outcomes (rehospitalization, mortality, quality of life) during a one-year follow-up; and (4) assess the effectiveness of an Information and Communication Technology (ICT) intervention designed to enhance social connectivity and emotional well-being.\n\nIn Phase 1, clinical data-including ejection fraction, congestive heart failure (CHF) stage, and comorbidity -will be collected using the 2024 Guidelines of the Taiwan Society of Cardiology, while sarcopenia will be identified via Asian Working Group for Sarcopenia (AWGS) guidelines. Physical, psychological, and social frail will be measured with the Tilburg Frailty Indicator (TFI) and Makizako's Social Frailty Questionnaire, respectively, and physical activity will be assessed using the IPAQ-S.\n\nPhase 2 will involve quarterly follow-ups over one year to compare health outcomes between metropolitan and rural settings, and to develop a predictive model of these outcomes. Phase 3 employs a quasi-experimental design with 90 participants randomized into three groups: an Information and Communication Technology (ICT) intervention group (using a dedicated app for at least 15 minutes daily, which monitors emotional status), a community-based social participation group, and a control group maintaining routine care. Key outcomes (mood, physical activity, frailty measures, and clinical status) will be assessed at baseline, immediately post-intervention, and three months thereafter.\n\nThis study is expected to identify significant differences between settings and demonstrate that a tailored Information and Communication Technology (ICT) intervention can improve social connectivity and clinical outcomes in older women with congestive heart failure (CHF).",[554,555,556,27],"65 Years Older","CHF - Congestive Heart Failure","Social Communication",[138,79,558,559,560,561,562,563],"Social Frailty","Congestive Heart Failure","Older Women","ICT Intervention","Metropolitan","Rural","2025-08-12",{"date":566,"type":32},"2025-08-15",{"date":568,"type":21},"2025-09-01",{"date":570,"type":21},"2028-07-31",{"name":572,"class":63},"Chang Gung University of Science and Technology",{"id":574,"slug":575,"hasResults":12,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":580,"targetDuration":4,"studyType":22,"phases":582,"briefSummary":583,"conditions":584,"keywords":585,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":592,"locationsCount":594},"100598492","phase-2-a-study-of-amc6156-in-people-with-sarcopenia-100598492","NCT07072195","A Study of AMC6156 in People With Sarcopenia","A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia","Inclusion Criteria:\n\n* Voluntary participation with written informed consent\n* Male ≥ 65 years or postmenopausal female\n* Diagnosed with sarcopenia:\n* ASM \\\u003C 7.0 kg\u002Fm² (men) or \\\u003C 5.4 kg\u002Fm² (women)\n* Plus low handgrip strength or SPPB ≤ 9\n* MNA screening score ≥ 8\n* Body weight ≥ 35 kg, BMI between 15-30 kg\u002Fm²\n* Willing and able to follow exercise and nutrition guidance\n\nExclusion Criteria:\n\n* Allergy to investigational drug\n* History of GI bleeding, ulcers, or severe liver\u002Fkidney\u002Fheart disease\n* QTc ≥ 450 ms with symptoms\n* Severe COPD, uncontrolled diabetes or thyroid disease\n* Diseases causing cachexia or muscle wasting (e.g., ALS, Parkinson's)\n* Vitamin D deficiency (\\\u003C10 ng\u002FmL), hemoglobin \\\u003C10 g\u002FdL\n* Severe psychiatric disorders or MMSE \\\u003C 21\n* Inability to walk or recent fracture\u002Fsurgery affecting mobility\n* Use of prohibited medications or recent participation in other clinical trials\n* Investigator deems the subject unsuitable for the study",{"count":581,"type":21},80,[24],"This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.",[27,79],[103],"2025-07-24",{"date":588,"type":32},"2025-07-29",{"date":590,"type":32},"2025-07-01",{"date":422,"type":21},{"name":593,"class":39},"Animuscure Inc.",4,{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":4,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":22,"phases":604,"briefSummary":606,"conditions":607,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":612,"leadSponsor":614,"locationsCount":64},"100597283","phase-3-rankl-inhibition-to-combat-sarcopenia-in-hip-fracture-patients-100597283","NCT07056478","RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients","RANKL Inhibition to Combat Sarcopenia in Hip Fracture Patients: A Pragmatic, Randomized Double-blind, Active-Controlled Trial","Inclusion Criteria:\n\n* Elderly aged 65 years or older\n* Diagnosed with sarcopenia following AWGS guidelines - low appendicular skeletal muscle mass measured by dual-energy x-ray absorptiometry (Cutoff: Male \\\u003C7.0kg\u002Fm2, and female \\\u003C5.4kg\u002Fm2) AND low handgrip strength (Cutoff: Male \\\u003C 28kg, Female \\\u003C18 kg) OR low physical performance (6-metre walk, cutoff: \\\u003C1.0m\u002Fs or 5-time chair stand test \\>=12s)\n* Diagnosed with a hip fracture from low-energy mechanism (e.g., falling from standing height) requiring an operation\n* Willing and able to comply with study protocol including follow-up evaluations.\n\nExclusion Criteria:\n\n* open fracture\n* multiple fractures\n* pathological fractures e.g., tumour, infection, etc.\n* history of medication or disease affecting bone metabolism e.g., hypo\u002Fhyperthyroidism\n* malignancy\n* chairbound or bedbound (unable to perform assessments)\n* serious cognitive problems e.g., severe dementia (unable to agree for consent) - renal impairment with glomerular filtration rate \\\u003C30 mL\u002Fmin\n* prior anti-osteoporotic medication e.g. bisphosphonates, denosumab, etc.\n* active infection,\n* severe malnutrition i.e. Mini Nutritional Assessment \\\u003C 17 points\n* serious neurological or neuromuscular conditions e.g. Parkinson's disease\n* uncontrolled chronic conditions e.g. poorly controlled diabetes mellitis\n* not anaesthetically fit for operation or conservative management",{"count":603,"type":21},130,[605],"PHASE3","The objective of this study is to conduct a pragmatic, randomized, double-blind, active-controlled trial to assess the efficacy of receptor activator of nuclear factor-kB ligand (RANKL) inhibition in the treatment of sarcopenia in hip fractures.",[27],"2025-06-29",{"date":610,"type":32},"2025-07-09",{"date":58,"type":21},{"date":613,"type":21},"2030-01-01",{"name":615,"class":63},"Prince of Wales Hospital, Shatin, Hong Kong",{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":12,"sex":17,"minAge":211,"maxAge":623,"enrollmentInfo":624,"targetDuration":4,"studyType":22,"phases":626,"briefSummary":627,"conditions":628,"keywords":4,"overallStatus":53,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":632,"leadSponsor":634,"locationsCount":64},"100592317","effects-of-nutritional-supplementation-of-leucine-and-polyunsaturated-fatty-acids-on-muscle-health-in-the-elderly-100592317","NCT06991855","Effects of Nutritional Supplementation of Leucine and Polyunsaturated Fatty Acids on Muscle Health in the Elderly","Explore the Effects of Nutritional Supplementation of Leucine and Polyunsaturated Fatty Acids on Muscle Health in the Elderly","Inclusion Criteria:\n\n* Age ≥ 50 years\n* ASMI \\\u003C 7 kg\u002Fm2 in men\n* ASMI \\\u003C 5.7 kg\u002Fm2 in women\n* Grip strength \\\u003C 28 kg in men\n* Grip strength \\\u003C 18 kg in women\n* Walk speed \\\u003C 1 m\u002Fs\n\nExclusion Criteria:\n\n* People who are allergic to supplements\n* cancer\n* heart failure\n* kidney disease\n* autoimmune disease\n* neurodegenerative disease","99 Years",{"count":625,"type":21},90,[50],"Population aging has become a significant global concern, and Taiwan is set to officially enter the \"super-aged society\" in 2025. As individuals age, various physiological functions gradually decline, including a reduction in muscle mass, which is a key aspect of the aging process.\n\nThis interventional study aims to investigate the effects of leucine-rich protein combined with polyunsaturated fatty acid supplementation on middle-aged and elderly individuals (aged 50 and above) who are at high risk for sarcopenia.",[79,27],{"date":630,"type":32},"2025-06-22",{"date":590,"type":21},{"date":633,"type":21},"2026-04-17",{"name":635,"class":63},"Chang Gung Memorial Hospital",{"id":637,"slug":638,"hasResults":12,"nctId":639,"briefTitle":640,"officialTitle":641,"acronym":4,"eligibilityCriteria":642,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":643,"enrollmentInfo":644,"targetDuration":4,"studyType":22,"phases":646,"briefSummary":647,"conditions":648,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":649,"lastUpdatePostDateStruct":650,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":655,"locationsCount":4},"100591897","blood-flow-restriction-training-for-age-related-sarcopenia-100591897","NCT06986395","Blood Flow Restriction Training for Age-Related Sarcopenia","The Efficacy of Blood Flow Restriction Training in Elderly Patients With Sarcopenia.","Inclusion Criteria:\n\n* Hospitalized patients aged ≥65 years\n* Diagnosed with sarcopenia per EWGSOP2019 criteria\n* Acute medical conditions stabilized for ≥4 weeks (e.g., resolved infections, controlled heart failure)\n\nExclusion Criteria:\n\n* Severe disability (Barthel Index ≤40)\n* Significant cognitive impairment (MMSE ≤18) or major psychiatric disorders (DSM-5 criteria)\n* Contraindications to blood flow restriction training:\n\n  * History\u002Fpredisposition to deep vein thrombosis\n  * Coagulopathy (INR \\>1.5, platelets \\\u003C100×10⁹\u002FL)\n  * Symptomatic varicose veins (CEAP class C4-C6)\n  * Uncontrolled hypertension (BP \\>160\u002F100 mmHg)\n  * Chronic lymphedema (ISL stage II-III)\n  * Peripheral artery disease (ABI ≤0.7)\n  * Active systemic infection (CRP \\>10 mg\u002FL)\n  * Malignancy (except non-melanoma skin cancer)\n  * Severe renal impairment (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²)\n  * Acute coronary syndrome within 3 months","100 Years",{"count":645,"type":21},40,[50],"Brief Title: Safe Exercise for Age-Related Muscle Loss in Hospitalized Seniors\n\nSummary:\n\nThis study compares two exercise methods to help older hospital patients (age 65+) rebuild muscle strength after being diagnosed with sarcopenia (age-related muscle loss). We want to know if using special pressure cuffs during light exercise works better than traditional strength training alone.\n\nWho Can Join:\n\nHospitalized seniors with stable health conditions Excludes those with severe disabilities, dementia, or certain blood circulation problems\n\nWhat We'll Do:\n\n40 participants will be randomly assigned to either:\n\nTraditional Training Group:\n\nUses weights\u002Fbands at 65-75% max capacity Arm\u002Fleg exercises 3x\u002Fweek for 4 weeks\n\nPressure Cuff Training Group:\n\nUses special cuffs on arms\u002Fthighs during lighter exercises (20% max capacity) Same exercise frequency with controlled pressure for safety\n\nWhat We'll Measure:\n\nHandgrip strength (main test at 0\u002F4\u002F12 weeks) Walking speed, balance tests, quality of life surveys Any side effects like dizziness\u002Fnausea\n\nSafety First:\n\nDoctors will check your health before starting. Nurses will monitor every session. We use medical-grade cuffs with safe pressure limits (arm: 80-100mmHg, thigh: 150-200mmHg). You can stop anytime if uncomfortable.\n\nWhy This Matters:\n\nThis could help hospitalized seniors regain strength faster using gentler exercises. All activities are supervised by rehabilitation specialists at West China Hospital, with ethics committee approval (IRB number required).",[27],"2025-05-20",{"date":651,"type":32},"2025-05-23",{"date":653,"type":21},"2025-05",{"date":538,"type":21},{"name":656,"class":63},"West China Hospital"]